The ABL tyrosine kinase inhibitor imatinib mesylate is highly effective in the treatment of CML and is increasingly used in the stem cell transplantation (SCT) setting. Since ABL-dependent intracellular signaling molecules are involved in T-cell activation, imatinib may affect T-cell responses in vivo, thus affecting T-cell function in CML patients, disrupting immune reconstitution after allogeneic SCT and/or impeding the graft-versusleukemia effect. Here we demonstrate that imatinib inhibits PHA-induced proliferation of normal peripheral blood mononuclear cells at in vitro concentrations (1-5 lmol/l) representative of the pharmacological doses used therapeutically in vivo. The effect is not dependent on antigen-presenting cells because CD3/CD28-induced T-cell stimulation was similarly inhibited by imatinib. Dose-dependent inhibition of the proliferative response of purified CD8 þ and CD4 þ T lymphocytes to anti-CD3/CD28 was similarly observed and associated with reduction in IFN-c production. The inhibitory effect could not be ascribed to an increased rate of apoptosis but the expression of activation markers on CD3 þ T cells was significantly reduced in the presence of imatinib (1-5 lmol/L). Inhibition of T-cell proliferation was reversible after removal of the drug from the cultures. Thus, imatinib inhibits T-cell proliferation in vitro, an effect that is APC-independent, reversible, and does not involve apoptosis induction.
Introduction
Imatinib mesylate (STI571, Gleevec, Novartis) is a highly effective and well-tolerated oral agent that has had a significant impact on the treatment of patients with chronic myeloid leukemia (CML). [1] [2] [3] [4] [5] By inhibiting the BCR-ABL protein kinase, imatinib targets the molecular event which forms the basis for CML. Although highly specific, imatinib occupies the ATPbinding site of several tyrosine kinase molecules such as ABL, 2,6-9 the stem cell factor receptor c-kit, 10 ,11 the plateletderived growth factor receptor (PDGFR), 6, 10, 12 and ARG. 13 Although imatinib is highly effective in the treatment of CML, long-term follow-up is lacking and allogeneic SCT remains the only proven curative option. Presently, it is unclear how best to incorporate imatinib into studies related to stem cell transplantation. Strategies include postponing transplantation pending some degree of imatinib-induced clearing of leukemic clones, reserving the drug until after marrow transplantation (using imatinib as an 'adjuvant' to marrow transplantation), or administration of the drug in situations of leukemic relapse after allogeneic SCT.
However, little is known about the effects of imatinib on nonmalignant (Philadelphia negative) hematopoietic cells. In the majority of studies, T lymphocytes of CML patients have been found to be Philadelphia negative and/or BCR-ABL negative. [14] [15] [16] In vitro studies have demonstrated that imatinib specifically inhibits or kills proliferating myeloid cell lines containing BCR-ABL, but is minimally harmful to normal cells. 6, 7, 17 The agent also reduces the formation of BCR-ABLpositive colony-forming units generated from CML patients in vitro by approximately 95% at imatinib concentrations of 1 mM. This selective inhibition of colony formation is observed over a 2-log dose range, with a maximal differential effect at 1 mmol/l. 7 Substantial in vivo inhibition of the enzymatic activity of BCR-ABL at a daily dose of 400 mg has been demonstrated, which correlates well with clinical response and with levels of the drug that kill CML cells in vitro. 2 However, several of the intracellular signaling molecules triggered by the ABL kinase are also involved in the activation pathways of immune cells. It has been shown that ABLÀ/À knockout (KO) mice have thymic and splenic atrophy and a substantial T-and B-cell lymphopenia. 18, 19 In contrast, the myeloid/macrophage lineages are unaffected. Although the follow-up of CML patients treated with imatinib is short, an increase in the incidence of infections and other malignancies has been reported. 20, 21 In light of these observations, we were concerned that inhibition of ABL kinases may have a detrimental effect on the immune response, and we sought to identify whether T-cell proliferative responses in vitro were affected by imatinib.
Materials and methods

T-cell isolation
Blood samples were obtained from 30 healthy donors with informed consent. Peripheral blood mononuclear cells (PBMCs) were isolated by Lymphoprep (Nycomed Pharma, Oslo, Norway) density gradient centrifugation. The following antibodies were used for the purification of CD3 þ T lymphocytes from freshly prepared PBMC: anti-CD14, anti-CD16, anti-CD19, anti-CD33, and anti-CD56 (all from Caltag, Towcester, UK). For the purification of CD4 þ and CD8 þ T cells, OKT8 (American Type Culture Collection, USA) or anti-CD4 antibodies (BD PharMingen, USA) were added, respectively. All antibodies were used for depletion in combination with sheep anti-mouse dynalbeads (Dynal (UK) Ltd). Purity was confirmed by FACS analysis and was 93.2-99% (data not shown).
(Life Technologies, UK). T-cell proliferation was assessed by 3 H-thymidine ( 3 H-TdR) (Amersham Pharmacia) incorporation added after 2-5 days and measured 18 h later. 22, 23 The effect of imatinib (a gift from Novartis Pharma, Basel, Switzerland) on T-cell stimulation was assessed as described previously for other drugs. [24] [25] [26] Where indicated, imatinib was added to T-cell cultures at serial concentrations (0, 1, 2, or 5 mmol/l). T-cell response to phytohemagglutinin (PHA) or CD3/ CD28 stimulation: Proliferation of PBMC (1 Â 10 5 /well) or purified T-lymphocyte subsets (5 Â 10 4 T cells/well) in response to PHA (2 mg/ml) 23 or anti-CD3/D28 Dynabeads (Dynal Biotech, Oslo, Norway) 22 was assessed in the presence or absence of imatinib after 72 h. Supernatants were harvested for cytokine analysis from proliferation assays, involving purified CD8 þ or CD4 þ lymphocytes, stimulated with anti-CD3/D28 Dynabeads prior to the addition of 3 H-TdR.
Mixed lymphocyte reaction (MLR)
PPD-specific CD4 þ T-cell clones: Tuberculin purified protein derivative (PPD)-specific T-cell clones were derived from an individual by culturing PBMC with 300 U/ml PPD (EVANS Vaccine Limited, Liverpool, UK) in RPMI/10% HS. PPD-specific T-cell lines were cloned by limiting dilution in U-bottomed 96-well plates (Nunc) in the presence of irradiated PBMC previously pulsed with 10 mg/ml of PHA (Murex Biotech, Dartford, UK) and rIL-2 (10 U/ml) (Roche, Mannheim, Germany). T-cell clones were stimulated every 7 days with irradiated PBMC previously pulsed with PPD (300 U/ml) in RPMI/10% HS and rIL-2. T-cell clones were used for proliferative tests 1 week from their last stimulation. For these experiments, PBMC were pulsed overnight with PPD (300 U/ml) or the irrelevant antigen, 8 Â 10 À2 U/ml tetanus toxoid (TT) (EVANS Vaccine Limited, Liverpool, UK), in the absence of imatinib. The following day, T-cell clones (1 Â 10 4 /well) were co-cultured with irradiated PBMC (1 Â 10 4 /well) in 96 U-bottomed well plates (200 ml total volume/well) with serial concentrations (0, 1, 2, or 5 mmol/l) of imatinib. After 72 h incubation, 3 HTdR-incorporation was measured.
Measurement of cytokine production
Supernatants for cytokine analysis were harvested after 24, 48, 72, and 96 h from wells in which purified CD4 þ or CD8 þ T lymphocytes (5 Â 10 4 T cells/well) were stimulated with anti-CD3/D28 Dynabeads in the presence (1-5 uM) or absence of imatinib. Samples were assayed for IFN-g (MS Biotechnology, UK), IL-5 (Biosource International, California, USA), and IL-10 (Pharmingen, USA) production by double antibody sandwich ELISA using a purified mAb, paired with a biotinylated mAb as previously described. 27 Absorbance values were measured using a Labsystems Multiscan Plus spectrophotometer at 450 nm and levels of cytokine estimated using the curve obtained from the set of standards.
The data were transferred to a computer for analysis using the Cytafzal programme.
Measurement of cell viability and apoptosis
PBMCs stimulated for 24-72 h with PHA or anti-CD3/D28 Dynabeads at various imatinib concentrations were labeled with FITC-conjugated annexin-V (BD PharMingen, USA) and ViaProbe 7-aminoactinomycin D (7-AAD; BD PharMingen). CD3 þ T lymphocytes were analyzed using a FACSCalibur flow cytometer and CellQuest software (Becton Dickinson, Mountain View, CA, USA). 23 Apoptotic cells were defined as annexin V þ / 7-AAD À . Positive controls were ultraviolet B (UVB312 nm) irradiated PBMCs (800 mJ/cm 2 ).
Measurement of T-cell activation
T-cell activation following 72 h stimulation with anti-CD3/D28, in the presence or absence of imatinib, was assessed by quantifying the number of CD3 þ T cells expressing the activation markers CD25, CD69, and HLA-DR. Briefly, T cells (1 Â 10 5 ) were incubated with the appropriate directly conjugated antibody for 30 min on ice. Cells were washed twice with ice-cold FACS buffer (PBS, 1% fetal calf serum, 0.05% sodium azide) and analyzed on a FACSCalibur flow cytometer (Becton Dickinson) using CellQuest software. Dead cells and debris were excluded by forward and side scatter gating.
Statistical analysis
Student's t-test analysis was used to compare different groups. P-values o0.05 were considered statistically significant.
Results
Inhibition of polyclonal mitogen-induced stimulation of T lymphocytes
Imatinib inhibited T-cell proliferation in the MLR in a dose-dependent fashion (Figure 1 ) at all stimulator Figure 1 Imatinib inhibits T-lymphocyte proliferation induced by allogeneic PBMC in a dose-dependent manner. Naïve CD4 þ T cells (5 Â 10 (PBMC) numbers analysed. Maximum inhibition was noted at the maximum imatinib concentration assessed: 5 mmol/l (median 53%, range 46-55%). The median inhibition was 16.4% (range 8-18.1%) and 28.4% (range 22.5-31%) at 1 and 2 mmol/l, respectively. The inhibitory effect was not increased if responder PBMCs were incubated with imatinib for 24 h prior to use in the MLR (data not shown).
Target population
T-cell proliferation in MLR is dependent on the presence of antigen-presenting cells (APC). To investigate the possibility that imatinib specifically targeted APC, we compared its effect on PHA-and CD3/CD28-induced stimulations, which are APCdependent and APC-independent, respectively. No difference was observed (Figure 2a) . At 1 mmol/l imatinib the mean 
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inhibitions of PBMC were 21 and 29% with PHA and CD3/ CD28, respectively, at 2 mmol/l imatinib the inhibitions were 38 and 47%, and at 5 mmol/l imatinib the inhibitions were 66 and 72%, respectively (Figure 2a) . The lack of requirement of APC for imatinib to exert its inhibitory effect on T cells was also supported by the observation that PPD-specific CD4 þ T-cell clones, in which APC were pulsed with the cognate antigen (PPD) in the absence of imatinib, were similarly inhibited (Figure 2b ). Mean inhibitions of 13, 27, and 55% were observed with imatinib at 1, 2, and 5 mmol/l, respectively. The PPDspecific T-cell clones did not proliferate in response to PBMC pulsed with irrelevant antigen (TT).
Having excluded the hypothesis that APC are the targets of imatinib-induced inhibition of T-cell proliferation, we asked whether different T-cell subsets were predominantly affected. The proliferative response of purified CD8 þ and CD4 þ T lymphocytes to CD3/CD28 antibodies was inhibited similarly by imatinib in a dose-dependent manner (Figure 2b) . At 1 mmol/l imatinib the inhibition of CD8 þ T cells was 31%, at 2 mmol/L imatinib the inhibition was 49%, and at 5 mmol/L imatinib the inhibition was 69%. The inhibitions of CD4 þ T cells were 29, 46, and 80% at 1, 2, and 5 mmol/l, respectively. Furthermore, no difference in the magnitude of inhibition of anti-CD3/28-induced proliferation of purified CD4CD45RA þ (naïve) and CD4CD45RO þ (memory) T cells was observed (data not shown).
Imatinib inhibits the production of IFN-g from CD8
þ and CD4
þ T cells
Cytokine analysis was performed to determine whether the Th phenotype of the purified CD8 þ or CD4 þ cells differed as a consequence of the presence of imatinib in the cultures. Imatinib resulted in reduction in IFN-g production by both CD8 þ and CD4 þ T cells after 48-96 h anti-CD3/CD28 antibody stimulation (Figure 3 ). In contrast, there was no reproducible effect on the production of either IL-4 or IL-10 (data not shown).
Imatinib mesylate does not increase apoptosis
It has been described that imatinib induces apoptosis and reduces proliferation of BCR-ABL þ cells. 7, 8 Therefore, the inhibitory effect observed in our T-cell cultures might result from apoptosis rather than functional inactivation. However, the fraction of apoptotic cells in the CD3 þ population after CD3/ CD28 stimulation in the presence of imatinib did not differ from controls without imatinib (Figure 4) . The fraction of apoptotic cells remained between 15 and 18% after incubation of PBMC with imatinib at concentrations of 1-5 mmol/l for 24-72 h.
A mechanism of suppression of T-cell proliferation by imatinib mesylate is decreased T-cell activation
When we analyzed the expression of T-cell activation markers on CD3 þ T lymphocytes isolated from five different donors following 72 h CD3/CD28 stimulation, a reduction in both the percentage and mean fluorescence intensity of CD25, CD69, and HLA-DR was observed ( Figure 5 ). This effect was most marked at the highest imatinib concentration assessed (5 mmol/ l). The percentage expression of CD25 and HLA-DR molecules on CD3 þ T lymphocytes was significantly reduced (Po0.05) at X1 mmol/l imatinib. Significant reduction in CD69 expression was observed at 5 mmol/l imatinib. 
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Inhibition of T-cell proliferation is reversible
In order to assess the duration of the inhibition, imatinib was removed from T-cell cultures and, after 48 h resting, T cells were re-stimulated with anti-CD3/CD28 Dynabeads. T-cell proliferation could be completely restored, thus demonstrating that the inhibitory effect is transient ( Figure 6 ).
Discussion
We have demonstrated that imatinib inhibits the proliferation and activation of T cells at in vitro concentrations representative of the pharmacological doses used therapeutically in vivo. This effect is reversible, APC-independent, and does not involve induction of apoptosis. The effect of imatinib on T-cell proliferation in vitro was assessed using an array of T-cell proliferative tests. The stimuli to induce T-cell proliferation in vitro included: histoincompatibility between cell populations (primary mixed lymphocyte reaction: MLR), nonspecific mitogens (PHA), direct T-cell activation (anti-CD3/CD28 antibodies), or cognate peptide presented in conjunction with the relevant MHC molecule (PPD-specific T-cell clones). T-cell populations in vivo are affected by the cytokine milieu, cell:cell interactions, and stromal influences. Although these assays underestimate the complexity of the immune system in vivo, they do assess the ability of T lymphocytes to respond to a range of stimuli.
The inhibitory effect on T-cell proliferation appears to be nonspecific since all proliferative assays were inhibited by imatinib concentrations X1 mmol/l. Inhibition of proliferation was also associated with inhibition of IFN-g production by both Imatinib-induced T-cell inhibition is reversible. Proliferation of CD4 þ T lymphocytes to anti-CD3/28 Dynabeads was measured after 72 h in the absence or presence of increasing concentrations of imatinib (0, 1, 2, or 5 mmol/l). Imatinib was then removed from the cultures and, after 48 h resting, T cells were restimulated with anti-CD3/ CD28. Data are representative of four experiments with similar results.
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þ and CD4 þ T lymphocytes. Although cytokines were assayed every 24 h over 4 days, there was no clear trend observed for IL-4 and IL-10 production by either CD8 þ or CD4 þ T lymphocytes. Thus, it appears that imatinib does not alter the Th phenotype of the T cells in culture. Reduction in production of IFN-g suggests that the effector function of T lymphocytes may be reduced in the presence of imatinib. A number of studies have demonstrated abnormal cytokine profiles in T lymphocytes stimulated ex vivo as part of mononuclear fractions isolated from untreated CML patients. A reduced capacity to produce Th1 cytokines and a shift toward a Th2 phenotype is well described in CML patients. [28] [29] [30] Restoration of Th1 cytokine synthesis by T cells of CML patients who had achieved durable complete cytogenetic remission for 42 years in response to IFN-a, but who had discontinued the drug, has been described. 31 The mechanisms underlying this abnormal cytokine profile are unclear, but recent evidence suggests that such T-cell abnormalities may be mediated indirectly by leukemia or APCs present in these fractions. Leukemic cells from CML patients have been shown to secrete the Th2 cytokine IL-10.
32 IL-10 can suppress the production of IL-2 and IFN-g and can affect the quality and magnitude of the immune response. 33 We have recently described abnormal function in vitro of dendritic cells (DCs) generated from PBMC of CML patients. 34 Further support is provided by the demonstration that the ex vivo cytokine-producing capacity of isolated CD4 þ T cells, depleted of leukemic and accessory cells, from CML patients in response to anti-CD3/CD28, was normal. 35 Another potential confounding factor when assessing the effect of imatinib in vivo is that imatinib affects APC development and function in vitro. 36 Appel et al 36 have reported that imatinib affects the differentiation of DCs generated from CD34 þ peripheral blood progenitor cells. This was associated with a reduced ability of DCs to induce primary cytotoxic Tlymphocyte (CTL) responses.
Other interactions than those proposed may be involved, and thus a study to analyze the effect of imatinib in vivo requires careful design. Lymphocytes should be stored from individuals before starting imatinib and taken at time intervals. Recent data suggest differences in the effect of imatinib on the function of B lymphocytes 37 and plasmacytoid DC 38 isolated from CML patients treated with imatinib in vivo, depending on their response to imatinib. Thus, such studies must involve comparisons of T-cell function between normal individuals and CML patients before and during treatment with imatinib.
There is some evidence that the inhibition of T-cell proliferation we have observed in vitro may be associated with a clinical effect. Although the follow-up for patients receiving imatinib is relatively short, an increase in the incidence of infections and other malignancies has been reported and this may be a result of immune dysfunction. 20, 21 Many studies show that T lymphocytes are not part of the Philadelphia-positive clone in CML patients, 15, 39 and that the majority of T cells are BCR-ABL negative. 14, 16 B-cell dysfunction has been suggested by the recent observation of hypogammaglobulinemia in CML patients (previously resistant or intolerant of IFN-a) who have been treated with imatinib. 37 It is unlikely that this was related to previous treatment with IFN-a, since this has never been reported, and levels of IgG were normal in all patients before imatinib therapy. Studies assessing B-cell function in imatinib-treated patients unexposed to IFN-a have not been published to date.
Our results raise questions that are central to the treatment of CML, especially in situations of minimal leukemic burden and normal APCs. After myeloablative allogeneic SCT, engraftment of normal donor dendritic cells is rapid. 40 Imatinib is increasingly used as a selective leukemia de-bulking agent prior to allografting, 41 or in treatment of relapse with or without donor lymphocyte infusions. [42] [43] [44] Our observations suggest that imatinib may influence T-cell immune responses in vivo. An adverse effect of IFN-a on transplantation outcome has been described previously, and this association was unexpected. 45 The reversibility of the imatinib-induced inhibition is in agreement with the lack of significant clinical impact and makes further investigation ex vivo of T-lymphocyte function in patients unlikely to be informative. However, it is possible that imatinib interferes with the expansion of graft-versus-leukemia effector T cells, thus impending or at least reducing the therapeutic efficacy of transplant or DLI. The effect of imatinib on immune responses in vivo warrants further investigation.
